Publications by authors named "Cynthia Wat"

Claim this Profile
O
Overrange dilution for improvement of hepatitis B core related antigen as a biomarker: protocol validation and examples for application.
Maria Pfefferkorn, Jessica Brehm, Martin Brehm, Fanny Honshoven, Danilo Deichsel, Cynthia Wat

Virology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B.
Jinlin Hou, Wenhong Zhang, Qing Xie, Rui Hua, Hong Tang, Cynthia Wat

N Engl J Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection.
Edward J Gane, Won Kim, Tien Huey Lim, Pisit Tangkijvanich, Jung-Hwan Yoon, Wattana Sukeepaisarnjaroen, Cynthia Wat

J Hepatol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single ascending dose study of single-stranded oligodeoxyribonucleotide RO7062931 in Chinese healthy volunteers.
Tsang Tommy Cheung, Andrea On Yan Luk, Yuchen Zhang, Vedran Pavlovic, Cynthia Wat

Clin Transl Sci· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study.
Milan J Sonneveld, Bettina E Hansen, Willem P Brouwer, Henry L-Y Chan, Teerha Piratvisuth, Cynthia Wat

J Infect Dis· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Cynthia Wat, Edward Gane, Man-Fung Yuen, Vedran Pavlovic, Henrik Mueller

Hepatology· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.
Edward Gane, Man-Fung Yuen, Dong Joon Kim, Henry Lik-Yuen Chan, Bernadette Surujbally, Cynthia Wat

Hepatology· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B.
Maria Pfefferkorn, Tina Schott, Stephan Böhm, Danilo Deichsel, Christin Felkel, Cynthia Wat

J Hepatol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis.
Milan J Sonneveld, Willem P Brouwer, Bettina E Hansen, Henry L-Y Chan, Teerha Piratvisuth, Cynthia Wat

Aliment Pharmacol Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: a systematic review and meta-analysis of individual participant data.
Vedran Pavlovic, Lei Yang, Henry Lik-Yuen Chan, Jinlin Hou, Harry L Janssen, Cynthia Wat

Antivir Ther· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.
Franziska Rinker, Corinna M Bremer, Kathrin Schröder, Steffen B Wiegand, Birgit Bremer, Cynthia Wat

Liver Int· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver safety assessment in clinical trials of new agents for chronic hepatitis B.
Robert J Fontana, Mark I Avigan, Harry L A Janssen, Arie Regev, Poonam Mishra, Cynthia Wat

J Viral Hepat· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B.
Lai Wei, Vedran Pavlovic, Aruna T Bansal, Xiaoping Chen, Graham R Foster, Cynthia Wat

J Viral Hepat· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study.
Milan J Sonneveld, Willem P Brouwer, Henry L-Y Chan, Teerha Piratvisuth, Ji-Dong Jia, Cynthia Wat

Lancet Gastroenterol Hepatol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
Lai Wei, Heiner Wedemeyer, Yun-Fan Liaw, Henry Lik-Yuen Chan, Teerha Piratvisuth, Cynthia Wat

PLoS One· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study.
Stefan Wirth, Hongfei Zhang, Winita Hardikar, Kathleen B Schwarz, Etienne Sokal, Cynthia Wat

Hepatology· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B.
Florian van Bömmel, Alena van Bömmel, Alexander Krauel, Cynthia Wat, Vedran Pavlovic

J Infect Dis· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
Barbara J Brennan, Annabelle Lemenuel-Diot, Eric Snoeck, Michael McKenna, Jonathan Solsky, Cynthia Wat

Br J Clin Pharmacol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C.
Kathleen B Schwarz, Jean P Molleston, Maureen M Jonas, Jessica Wen, Karen F Murray, Cynthia Wat

J Pediatr Gastroenterol Nutr· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term growth outcomes in children treated for chronic hepatitis C.
Maureen M Jonas, Kathleen B Schwarz, Regino Gonzalez-Peralta, Steven Lobritto, Jean P Molleston, Cynthia Wat

J Pediatr· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Patrick Marcellin, Antonio Craxi, Carlos E Brandao-Mello, Adrian M Di Bisceglie, Pietro Andreone, Cynthia Wat

J Clin Gastroenterol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device.
Peter Varunok, Eric Lawitz, Kimberly L Beavers, Gary Matusow, Ruby Leong, Cynthia Wat

Patient Prefer Adherence· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to enfuvirtide and its impact on treatment efficacy.
Jürgen Rockstroh, Edwin Dejesus, Lucille Donatacci, Cynthia Wat, Anne Bertasso

AIDS Res Hum Retroviruses· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Mark Nelson, Keikawus Arastéh, Bonaventura Clotet, David A Cooper, Keith Henry, Cynthia Wat

J Acquir Immune Defic Syndr· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of enfuvirtide in a patient with impaired renal function.
Clifford Leen, Cynthia Wat, Keith Nieforth

Clin Infect Dis· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis